Cargando…

Posterior lens capsule neovascularization treated with anti-VEGF complicated by phacogenic uveitis

PURPOSE: To report a case of neovascularization of posterior capsule (NVPC) successfully treated with intravitreal ranibizumab (Lucentis) and neodymium:YAG (Nd:YAG) capsulotomy, followed by phacogenic uveitis. OBSERVATIONS: We report a systemically otherwise healthy 81-year-old male presenting with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Felicia, Mandelcorn, Efrem D., Somani, Sohel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652777/
https://www.ncbi.nlm.nih.gov/pubmed/33204896
http://dx.doi.org/10.1016/j.ajoc.2020.100943
Descripción
Sumario:PURPOSE: To report a case of neovascularization of posterior capsule (NVPC) successfully treated with intravitreal ranibizumab (Lucentis) and neodymium:YAG (Nd:YAG) capsulotomy, followed by phacogenic uveitis. OBSERVATIONS: We report a systemically otherwise healthy 81-year-old male presenting with unilateral NVPC and iris (NVI) occurring five years after a central retinal vein occlusion. A single intravitreal injection of ranibizumab led to complete regression of NVPC and NVI within three weeks after which a Nd:YAG capsulotomy was performed. Two weeks later, the patient returned with a severe inflammatory reaction diagnosed as phacogenic uveitis and treated with surgical capsular bag/intraocular lens complex removal and peripheral pan-retinal photocoagulation. One-year follow-up demonstrated no recurrence of NVPC. Visual acuity remained at baseline of light perception. CONCLUSIONS: We acknowledge that intravitreal anti-vascular endothelial growth factor treatment with Nd:YAG capsulotomy for NVPC is a rational option, but raise awareness to the rare possibility of phacogenic uveitis.